

# Contrast Media/Contrast Agent Market Is Booming Worldwide 2022-2028 | Lantheus Medical Imaging, GE Healthcare, Bayer

*Contrast media or contrast agent is used in medical imaging to enhance the image of body parts generated through X-rays*

SEATTLE, WASHINGTON, UNITED STATES, January 4, 2022

/EINPresswire.com/ -- Contrast Media have different properties that make them suitable for use in the radiology setting. They usually have increased viscosity and osmolality. Their properties also play a role in the contrast reactions. Ionic agents are those that have more molecules per kilogram of water. However, gadolinium-based contrasts have varying radiodensity and may be more appropriate in certain circumstances. The patient is generally not at risk for a reaction to these compounds, but they should be monitored carefully for any serious side effects.



The use of contrast media has increased dramatically over the years. They are often used in special procedures. While the difference in tissue density is not large enough to allow for adequate contrast, they do give a better picture of the body. Intravascular contrast agents are the most common and widely used in CT and MRI scans. As a result, a high-density image is more readily available. This is important to ensure that the patient is safe during the procedure.

For more information, contact [coherentmarketinsights@coherentmarketinsights.com](mailto:coherentmarketinsights@coherentmarketinsights.com)

<https://www.coherentmarketinsights.com/insight/request-pdf/1210>

COHERENT MARKET INSIGHTS

Major players operating in the global [contrast media/contrast agent market](#) are focused on approval and launch of new products to expand their product portfolio. For instance, in July 2019, Bracco Diagnostics Inc., a subsidiary of Bracco Imaging S.p.A., launched an interactive and customizable media kit for enhancing the user experience and increasing physician referrals.

High prevalence of cancer is expected to propel growth of the global contrast media/contrast agent market over the forecast period.

For instance, according to the study, 'Cancer statistics for adults aged 85 years and older, 2019', published in ACS CA: A Cancer Journal for Clinicians, in August 2019, in 2019, the projected number of cancer cases and deaths was 140,690 and 103,250 respectively, among adults aged 85 years and older in the U.S.

Moreover, approval and launch of new products is also expected to propel growth of the global contrast media/contrast agent market over the forecast period. For instance, in March, 2017, GE Healthcare launched Clariscan, a gadolinium-based contrast agent designed to support effective visualization of abnormalities in the spine, brain and associated tissues.

Expansion of indication is expected to offer lucrative growth opportunities for players in the global contrast media/contrast agent market.

For instance, in May 2017, the Food and Drug Administration expanded indication for GE Healthcare's Visipaque (iodixanol) for use in coronary computed tomography angiography (CCTA) for diagnostic evaluation of adult and pediatric patients 12 years of age or older with suspected coronary artery disease.

Major players operating in the global contrast media/contrast agent market are focused on approval and launch of new products to expand their product portfolio.

For instance, in July 2019, the U.S. Food and Drug Administration approved Bayer HealthCare's Gadavist (gadobutrol) injection to be used as the first contrast agent for cardiac MRI in the patients suspected to suffer from the coronary artery disease.

Side effects of contrast agents such as kidney diseases and high cost associated with the contrast media injectors are some of the factors hindering growth of the global contrast media/contrast agent market.

Side effects of contrast agents such as kidney diseases and high cost associated with the contrast media injectors are some of the factors hindering growth of the global contrast media/contrast agent market.

For more information on this report, visit <https://www.coherentmarketinsights.com/insight/buy-now/1210>

Side effects of contrast agents such as kidney diseases and high cost associated with the contrast media injectors are some of the factors hindering growth of the global contrast media/contrast agent market.

Side effects of contrast agents such as kidney diseases and high cost associated with the contrast media injectors are some of the factors hindering growth of the global contrast media/contrast agent market.

000000 00000000 000000/00000000 00000 000000: 00 0000000000

Major players operating in the global contrast media/contrast agent market are also focused on approval and launch of new products to expand their product portfolio. For instance, in September 2019, Bayer HealthCare launched Medrad Stellant Flex CT injection system in order to offer user-driven system, individualized patient protocols and personalized imaging. Similarly, in 2016, Bayer AG received the U.S Food and Drug Administration's approval for Gadavist (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate renal artery disease use in adult and pediatric patients.

000000 00000000 00000/00000000 00000 000000: 000000000000

በጥሩ ምርቶች በጣም ተወስኖ መጣውን አይመለከትም፡፡

## Microbubble Contrast Media

## Iodinated Contrast Media

## Barium-Based Contrast Media

## Gadolinium-Based Contrast Media

මම මගේ මාර්ගය මම මාර්ගය මම මාර්ගයමාර්ගයමාර්ගය, මාර්ගයමාර්ගය මාර්ගය/මාර්ගයමාර්ගය මාර්ගය මාර්ගය මම මාර්ගයමාර්ගය මාර්ගය:

Oral

Rectal

Intravenous

Urethral

[illegible]

Neurological Disorders

Nephrological Disorders

Cardiovascular Disorders

Gastrointestinal Disorders

Oncology

Musculoskeletal Disorders

Our report covers the market for **Contrast Media**, **Diagnostic Imaging** and **Therapeutic Imaging** across the following regions:

Hospitals

Ambulatory Surgical Centers

Diagnostic Clinics

Our report covers the market for **Contrast Media**, **Diagnostic Imaging** and **Therapeutic Imaging** across the following regions:

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

Our report covers the market for **Contrast Media**, **Diagnostic Imaging** and **Therapeutic Imaging** across the following regions:  
<https://www.coherentmarketinsights.com/insight/request-sample/1210>

Our report covers the market for **Contrast Media**, **Diagnostic Imaging** and **Therapeutic Imaging** across the following regions:  
Lantheus Medical Imaging, GE Healthcare, Bayer HealthCare, Bracco Imaging S.p.A, NanoPET Pharma GmbH, Guerbet Group, CMC Contrast AB, Daiichi Sankyo, and Subhra Pharma Private Limited

Our report covers the market for **Contrast Media**, **Diagnostic Imaging** and **Therapeutic Imaging** across the following regions:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Mr. Shah

Coherent Market Insights Pvt. Ltd.

+1 206-701-6702

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/559802412>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.